Published in Clinical Oncology Week, March 8th, 2010
"Farletuzumab (MORAb-003) is a humanized mAb with high affinity for folate receptor alpha (FRalpha), a 38 kDa GPI-anchored protein that is overexpressed in 90% of epithelial ovarian cancers. AREAS COVERED IN THIS REVIEW: Preclinical and clinical trials, published or presented at national meetings from 2006 to the present, are presented in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.